Cannabidiol Modulates Neuroinflammatory Markers in a PTSD Model Conducted on Female Rats.

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Post-traumatic stress disorder (PTSD) is a prevalent neuropsychiatric condition often linked to neuroinflammation, with higher incidence in women.
• Cannabidiol (CBD), a non-psychoactive compound from cannabis, is being investigated for its therapeutic potential in PTSD.
• Neuroinflammation, particularly involving cytokines like IL-1β and IL-6, plays a significant role in PTSD pathophysiology.

Purpose of the Study:

• To investigate the efficacy of chronic cannabidiol (CBD) treatment in mitigating PTSD-like behaviors and associated neuroinflammation in a female rat model.
• To assess the impact of CBD on fear extinction, learned helplessness, and specific inflammatory markers in key brain regions.

Main Methods:

• A validated rat model of PTSD was induced using severe foot shock and contextual situational reminders (SRs).
• Female rats received daily CBD injections for three weeks during the SR period.
• Behavioral tests included extinction trials and the forced swim test (FST).
• Post-mortem analysis of brain tissues (mPFC and vSUB) examined inflammatory markers (IL-1β, IL-6).

Main Results:

• Chronic CBD treatment reversed fear extinction deficits and reduced learned helplessness in the FST.
• CBD administration significantly decreased the upregulation of interleukin-1 beta (IL-1β) in the medial prefrontal cortex (mPFC).
• CBD treatment downregulated interleukin-6 (IL-6) expression in the ventral subiculum (vSUB) and normalized its expression in the mPFC.

Conclusions:

• Cannabidiol demonstrates significant potential in inhibiting the development of PTSD-like behaviors.
• CBD treatment effectively suppresses key neuroinflammatory markers in the mPFC and vSUB, suggesting a neuroprotective role.
• These findings support CBD as a promising therapeutic agent for PTSD, particularly by targeting neuroinflammation.